Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DUK-CPG-001
- Development stage
- Phase 2
- Lead developer
- Duke University
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
DUK-CPG-001 is a synthetic CpG-rich oligonucleotide that acts as an agonist of toll-like receptor 9 (TLR9). By binding to and activating TLR9 in monocytes/macrophages, plasmacytoid dendritic cells, natural killer (NK) cells, and B cells, it stimulates the innate immune system. This activation leads to the production of T-helper cells and induction of immune signaling pathways. The drug has been investigated primarily as an immunopotentiating agent in cancer immunotherapy settings, including use as an adjuvant following allogeneic stem cell transplantation for hematologic malignancies[1][2][3][5].
- Other names
- TLR9 agonist DUK-CPG-001TLR-9 agonist DUK-CPG-001TLR 9 agonist DUK-CPG-001
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on DUK-CPG-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DUK-CPG-001.